Biology and clinical relevance of chemokines and chemokine receptors CXCR4 and CCR5 in human diseases

Chemokines and their receptors are implicated in a wide range of human diseases, including acquired immune deficiency syndrome (AIDS). The entry of human immunodeficiency virus type 1 (HIV-1) into a cell is initiated by the interaction of the virus's surface envelope proteins with two cell surface components of the target cell, namely CD4 and a chemokine co-receptor, usually CXCR4 or CCR5. Typical anti-HIV-1 agents include protease and reverse transcriptase inhibitors, but the targets of these agents tend to show rapid mutation rates. As such, strategies based on HIV-1 co-receptors have appeal because they target invariant host determinants. Chemokines and their receptors are also of general interest since they play important roles in numerous physiological and pathological processes in addition to AIDS. Therefore, intensive basic and translational research is ongoing for the dissection of their structure − function relationships in an effort to understand the molecular mechanism of chemokine − receptor interactions and signal transductions across cellular membranes. This paper reviews and discusses recent advances and the translation of new knowledge and discoveries into novel interventional strategies for clinical application.

[1]  村上 努.  A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection , 1998 .

[2]  M. Parmentier,et al.  Characterization of the role of the N-loop of MIP-1β in CCR5 binding , 2002 .

[3]  William C. Olson,et al.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.

[4]  Zi-Xuan Wang,et al.  CXCR4 Sequences Involved in Coreceptor Determination of Human Immunodeficiency Virus Type-1 Tropism , 1998, The Journal of Biological Chemistry.

[5]  R. Weiss,et al.  Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion , 1997, Journal of virology.

[6]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[7]  N. Aiyar,et al.  Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists. , 2001, Immunology letters.

[8]  Jean Salamero,et al.  HIV Coreceptor Downregulation as Antiviral Principle: SDF-1α–dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication , 1997, The Journal of experimental medicine.

[9]  T. Schwartz,et al.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.

[10]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[11]  C. Boshoff,et al.  Molecular Mimicry of Human Cytokine and Cytokine Response Pathway Genes by KSHV , 1996, Science.

[12]  R. Cooke,et al.  The three-dimensional solution structure of RANTES. , 1995, Biochemistry.

[13]  W. O'brien,et al.  Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions , 1996, Journal of virology.

[14]  D. Dimitrov,et al.  Evidence for Cell-Surface Association Between Fusin and the CD4-gp120 Complex in Human Cell Lines , 1996, Science.

[15]  N. Heveker,et al.  Identification of Residues of CXCR4 Critical for Human Immunodeficiency Virus Coreceptor and Chemokine Receptor Activities* , 2000, The Journal of Biological Chemistry.

[16]  E. Fernandez,et al.  Crystal structure of chemically synthesized [N33A] stromal cell-derived factor 1α, a potent ligand for the HIV-1 “fusin” coreceptor , 1998 .

[17]  T. Schwartz,et al.  A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. , 1997, Science.

[18]  A. Trautmann,et al.  Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides , 1998, Current Biology.

[19]  R. Doms,et al.  A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor , 1997, The Journal of experimental medicine.

[20]  R. Redfield,et al.  Clinical use of CCR5 inhibitors in HIV and beyond , 2011, Journal of Translational Medicine.

[21]  P. Murphy.  The molecular biology of leukocyte chemoattractant receptors. , 1994, Annual review of immunology.

[22]  M. Kavanaugh,et al.  A Critical Site in the Core of the CCR5 Chemokine Receptor Required for Binding and Infectivity of Human Immunodeficiency Virus Type 1* , 1999, The Journal of Biological Chemistry.

[23]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[24]  Oliver Hartley,et al.  Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  B. Sykes,et al.  Solution structure and basis for functional activity of stromal cell‐derived factor‐1; dissociation of CXCR4 activation from binding and inhibition of HIV‐1 , 1997, The EMBO journal.

[26]  Zhaowen Luo,et al.  Structural and Functional Characterization of Human CXCR4 as a Chemokine Receptor and HIV-1 Co-receptor by Mutagenesis and Molecular Modeling Studies* , 2001, The Journal of Biological Chemistry.

[27]  J. Sodroski,et al.  Exploring the Stereochemistry of CXCR4-Peptide Recognition and Inhibiting HIV-1 Entry with d-Peptides Derived from Chemokines* , 2002, The Journal of Biological Chemistry.

[28]  E. Berger,et al.  Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5. , 2004, Blood.

[29]  Stephen C Peiper,et al.  Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. , 2003, Angewandte Chemie.

[30]  R. Redfield,et al.  Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. , 2008, The Journal of infectious diseases.

[31]  M. Peitsch,et al.  Selectivity and antagonism of chemokine receptors , 1996, Journal of leukocyte biology.

[32]  B. Dewald,et al.  N-terminal Peptides of Stromal Cell-derived Factor-1 with CXC Chemokine Receptor 4 Agonist and Antagonist Activities* , 1998, Journal of Biological Chemistry.

[33]  D. Richman,et al.  SMM-chemokines: a class of unnatural synthetic molecules as chemical probes of chemokine receptor biology and leads for therapeutic development. , 2006, Chemistry & biology.

[34]  M. Matsuoka,et al.  Structural Basis for the Interaction of CCR5 with a Small Molecule, Functionally Selective CCR5 Agonist , 2006, The Journal of Immunology.

[35]  J. Hall,et al.  Attachment of C-terminus of SDF-1 enhances the biological activity of its N-terminal peptide. , 1999, Biochemical and biophysical research communications.

[36]  J. Moore,et al.  AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.

[37]  Marc Parmentier,et al.  The Core Domain of Chemokines Binds CCR5 Extracellular Domains while Their Amino Terminus Interacts with the Transmembrane Helix Bundle* , 2003, The Journal of Biological Chemistry.

[38]  Timothy N. C. Wells,et al.  Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R. Doms,et al.  Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Lederman,et al.  Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. , 2008, The Journal of infectious diseases.

[41]  James W. Hall,et al.  Molecular modeling and site‐directed mutagenesis of CCR5 reveal residues critical for chemokine binding and signal transduction , 2000, European journal of immunology.

[42]  John P. Moore,et al.  Alanine Substitutions of Polar and Nonpolar Residues in the Amino-Terminal Domain of CCR5 Differently Impair Entry of Macrophage- and Dualtropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[43]  H. Dohlman,et al.  Identification of Allosteric Peptide Agonists of CXCR4* , 2003, The Journal of Biological Chemistry.

[44]  J. Gershoni,et al.  HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  A. LiWang,et al.  The solution structure of the anti‐HIV chemokine vMIP‐II , 1999, Protein science : a publication of the Protein Society.

[46]  R. Weiss,et al.  Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus , 1991, Virology.

[47]  D. S. Garrett,et al.  High-resolution solution structure of the beta chemokine hMIP-1 beta by multidimensional NMR. , 1994, Science.

[48]  Won-Tak Choi,et al.  Distinct Functional Sites for Human Immunodeficiency Virus Type 1 and Stromal Cell-Derived Factor 1α on CXCR4 Transmembrane Helical Domains , 2005, Journal of Virology.

[49]  William C. Olson,et al.  Amino-Terminal Substitutions in the CCR5 Coreceptor Impair gp120 Binding and Human Immunodeficiency Virus Type 1 Entry , 1998, Journal of Virology.

[50]  M. Kaul,et al.  Neuronal Apoptotic Signaling Pathways Probed and Intervened by Synthetically and Modularly Modified (SMM) Chemokines* , 2007, Journal of Biological Chemistry.

[51]  Robin A. Weiss,et al.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain , 1986, Cell.

[52]  R. Doms,et al.  Safe use of the CXCR4 inhibitor ALX40-4C in humans. , 2001, AIDS research and human retroviruses.

[53]  Z. Luo,et al.  Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II. , 2000, Biochemistry.

[54]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[55]  D. Thompson,et al.  Entry of R5X4 and X4 human immunodeficiency virus type 1 strains is mediated by negatively charged and tyrosine residues in the amino-terminal domain and the second extracellular loop of CXCR4. , 2000, Virology.

[56]  C. Strader,et al.  Structure and function of G protein-coupled receptors. , 1994, Annual review of biochemistry.

[57]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[58]  David W. Ritchie,et al.  Modeling the Structural Basis of Human CCR5 Chemokine Receptor Function: From Homology Model Building and Molecular Dynamics Validation to Agonist and Antagonist Docking , 2006, J. Chem. Inf. Model..

[59]  Elias Lolis,et al.  Structure, function, and inhibition of chemokines. , 2002, Annual review of pharmacology and toxicology.

[60]  Ying Li,et al.  Crystal Structure and Structural Mechanism of a Novel Anti-Human Immunodeficiency Virus and d-Amino Acid-Containing Chemokine , 2007, Journal of Virology.

[61]  S. Climie,et al.  Antiherpetic activities of N-alpha-acetyl-nona-D-arginine amide acetate. , 1995, Drugs under experimental and clinical research.

[62]  Q. Sattentau,et al.  Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding , 1993, Journal of virology.

[63]  T. Schulz,et al.  The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion? , 1991, AIDS research and human retroviruses.

[64]  J. Karn,et al.  An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[65]  C. Boshoff,et al.  Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. , 1997, Science.

[66]  G. Lambeau,et al.  A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor. , 2001, Molecular pharmacology.

[67]  B. Premack,et al.  Chemokine receptors: Gateways to inflammation and infection , 1996, Nature Medicine.

[68]  J. Sodroski,et al.  A Tyrosine-Rich Region in the N Terminus of CCR5 Is Important for Human Immunodeficiency Virus Type 1 Entry and Mediates an Association between gp120 and CCR5 , 1998, Journal of Virology.

[69]  Kouji Matsushima,et al.  The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.

[70]  M. Matsuoka,et al.  Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. , 2001, Bioorganic & medicinal chemistry letters.

[71]  Masahiko Kuroda,et al.  Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development , 1998, Nature.

[72]  Joseph Sodroski,et al.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.

[73]  James W. Hall,et al.  The role of positively charged residues in CXCR4 recognition probed with synthetic peptides. , 1999, Biochemical and Biophysical Research Communications - BBRC.

[74]  J. Goudsmit,et al.  ASSOCIATION BETWEEN BIOLOGICAL PROPERTIES OF HUMAN IMMUNODEFICIENCY VIRUS VARIANTS AND RISK FOR AIDS AND AIDS MORTALITY , 1989, The Lancet.

[75]  J. Demartino,et al.  Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Helen M. Blau,et al.  Biological Progression from Adult Bone Marrow to Mononucleate Muscle Stem Cell to Multinucleate Muscle Fiber in Response to Injury , 2002, Cell.

[77]  B. Cullen,et al.  HIV‐1‐induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR‐5 co‐receptor , 1997, The EMBO journal.

[78]  Thomas P. Sakmar,et al.  Analysis of the Mechanism by Which the Small-Molecule CCR5 Antagonists SCH-351125 and SCH-350581 Inhibit Human Immunodeficiency Virus Type 1 Entry , 2003, Journal of Virology.

[79]  Anandan Palani,et al.  Interaction of small molecule inhibitors of HIV-1 entry with CCR5. , 2006, Virology.

[80]  C. Broder,et al.  CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. , 1996, Science.

[81]  C. Cheng‐Mayer,et al.  Biologic features of HIV-1 that correlate with virulence in the host. , 1988, Science.

[82]  M. Maccoss,et al.  Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket. , 2003, Biochemistry.

[83]  N. Heveker,et al.  Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity , 1997, Journal of virology.

[84]  E. Clercq,et al.  Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4 , 1997, The Journal of experimental medicine.

[85]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[86]  E. Fernandez,et al.  Comparison of the structure of vMIP-II with eotaxin-1, RANTES, and MCP-3 suggests a unique mechanism for CCR3 activation. , 2000, Biochemistry.

[87]  Z. Huang,et al.  Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis. , 2000, Pharmacology & therapeutics.

[88]  R. Bronson,et al.  Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[89]  M. Goldsmith,et al.  Multiple Extracellular Elements of CCR5 and HIV-1 Entry: Dissociation from Response to Chemokines , 1996, Science.

[90]  Marc Parmentier,et al.  Regions in β-Chemokine Receptors CCR5 and CCR2b That Determine HIV-1 Cofactor Specificity , 1996, Cell.

[91]  M. Baggiolini,et al.  HIV blocked by chemokine antagonist , 1996, Nature.

[92]  Menico Rizzi,et al.  Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES , 2001, Nature Structural Biology.

[93]  Stephen C. Peiper,et al.  Identification of CXCR4 Domains That Support Coreceptor and Chemokine Receptor Functions , 1999, Journal of Virology.

[94]  M. Parmentier,et al.  CC chemokine MIP-1 beta can function as a monomer and depends on Phe13 for receptor binding. , 2000, Biochemistry.

[95]  M. Parmentier,et al.  Characterization of the role of the N-loop of MIP-1 beta in CCR5 binding. , 2002, Biochemistry.

[96]  C. Broder,et al.  Substitutions in a Homologous Region of Extracellular Loop 2 of CXCR4 and CCR5 Alter Coreceptor Activities for HIV-1 Membrane Fusion and Virus Entry* , 2000, The Journal of Biological Chemistry.

[97]  S. O. Smith,et al.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[98]  Antonio Carrieri,et al.  Biological Profiling of Anti‐HIV Agents and Insight into CCR5 Antagonist Binding Using in silico Techniques , 2009, ChemMedChem.

[99]  B Dewald,et al.  Human chemokines: an update. , 1997, Annual review of immunology.

[100]  J. Hoxie,et al.  Role of the amino-terminal extracellular domain of CXCR-4 in human immunodeficiency virus type 1 entry. , 1997, Virology.

[101]  R. Offord,et al.  Highly potent, fully recombinant anti-HIV chemokines: Reengineering a low-cost microbicide , 2008, Proceedings of the National Academy of Sciences.

[102]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[103]  F. de Wolf,et al.  Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV‐1 phenotype , 1992, AIDS.

[104]  C. Broder,et al.  Mutagenesis of CXCR4 Identifies Important Domains for Human Immunodeficiency Virus Type 1 X4 Isolate Envelope-Mediated Membrane Fusion and Virus Entry and Reveals Cryptic Coreceptor Activity for R5 Isolates , 1999, Journal of Virology.

[105]  S. Mummidi,et al.  CC Chemokine Receptor 5-Mediated Signaling and HIV-1 Co-receptor Activity Share Common Structural Determinants , 1997, The Journal of Biological Chemistry.

[106]  A. Maynard,et al.  Naturally Occurring CCR5 Extracellular and Transmembrane Domain Variants Affect HIV-1 Co-receptor and Ligand Binding Function* , 1999, The Journal of Biological Chemistry.

[107]  M. Kaul,et al.  Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[108]  M. Goldsmith,et al.  Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[109]  B. Kobilka,et al.  Adrenergic receptors as models for G protein-coupled receptors. , 1992, Annual review of neuroscience.

[110]  Won-Tak Choi,et al.  Unique Ligand Binding Sites on CXCR4 Probed by a Chemical Biology Approach: Implications for the Design of Selective Human Immunodeficiency Virus Type 1 Inhibitors , 2005, Journal of Virology.

[111]  A. Proudfoot.  Chemokine receptors: multifaceted therapeutic targets , 2002, Nature Reviews Immunology.

[112]  Shoshana J. Wodak,et al.  The TXP Motif in the Second Transmembrane Helix of CCR5 , 2001, The Journal of Biological Chemistry.

[113]  S. Nishikawa,et al.  Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1 , 1996, Nature.

[114]  Marc Parmentier,et al.  The Second Extracellular Loop of CCR5 Is the Major Determinant of Ligand Specificity* , 1997, The Journal of Biological Chemistry.

[115]  J. Hall,et al.  A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II. , 2000, Biochemistry.